CA2870711A1 - Neuroprotective composition and method of use - Google Patents
Neuroprotective composition and method of use Download PDFInfo
- Publication number
- CA2870711A1 CA2870711A1 CA2870711A CA2870711A CA2870711A1 CA 2870711 A1 CA2870711 A1 CA 2870711A1 CA 2870711 A CA2870711 A CA 2870711A CA 2870711 A CA2870711 A CA 2870711A CA 2870711 A1 CA2870711 A1 CA 2870711A1
- Authority
- CA
- Canada
- Prior art keywords
- polyarginine peptide
- peptide
- cysteines
- polyarginine
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title abstract description 30
- 230000000324 neuroprotective effect Effects 0.000 title description 4
- 108010011110 polyarginine Proteins 0.000 claims abstract description 35
- 235000018417 cysteine Nutrition 0.000 claims abstract description 33
- 235000009697 arginine Nutrition 0.000 claims abstract description 19
- 150000001945 cysteines Chemical group 0.000 claims abstract description 19
- 230000006378 damage Effects 0.000 claims abstract description 15
- 208000014674 injury Diseases 0.000 claims abstract description 14
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 12
- 150000001484 arginines Chemical class 0.000 claims abstract description 10
- 230000001537 neural effect Effects 0.000 claims abstract description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 5
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 2
- 230000003466 anti-cipated effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 208000029028 brain injury Diseases 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 208000006011 Stroke Diseases 0.000 description 22
- 208000030886 Traumatic Brain injury Diseases 0.000 description 19
- 230000009529 traumatic brain injury Effects 0.000 description 18
- 210000001525 retina Anatomy 0.000 description 12
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 10
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000004224 protection Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000002438 mitochondrial effect Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000004112 neuroprotection Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000016273 neuron death Effects 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 231100000318 excitotoxic Toxicity 0.000 description 4
- 230000003492 excitotoxic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 3
- 208000005400 Synovial Cyst Diseases 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000003961 neuronal insult Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 210000001116 retinal neuron Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000013883 Blast injury Diseases 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 229940117892 Glutamate receptor agonist Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001181114 Neta Species 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010048955 Retinal toxicity Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003823 glutamate receptor agonist Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000005060 membrane bound organelle Anatomy 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000005731 poly ADP ribosylation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 231100000385 retinal toxicity Toxicity 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013417 toxicology model Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625349P | 2012-04-17 | 2012-04-17 | |
| US61/625,349 | 2012-04-17 | ||
| PCT/US2013/036938 WO2013158739A1 (en) | 2012-04-17 | 2013-04-17 | Neuroprotective composition and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2870711A1 true CA2870711A1 (en) | 2013-10-24 |
Family
ID=49384027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2870711A Abandoned CA2870711A1 (en) | 2012-04-17 | 2013-04-17 | Neuroprotective composition and method of use |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150126457A1 (enExample) |
| EP (1) | EP2872160A4 (enExample) |
| JP (1) | JP2015514771A (enExample) |
| AU (1) | AU2013249337A1 (enExample) |
| CA (1) | CA2870711A1 (enExample) |
| WO (1) | WO2013158739A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2870711A1 (en) | 2012-04-17 | 2013-10-24 | Brown University | Neuroprotective composition and method of use |
| CN106170491B (zh) * | 2013-10-30 | 2020-07-24 | 阿尔杰妮卡治疗学有限公司 | 神经保护肽 |
| US20170114093A1 (en) * | 2015-05-29 | 2017-04-27 | Andrew Peter Mallon | Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection |
| US20210101935A1 (en) | 2019-10-02 | 2021-04-08 | Brown University | Cyclic peptidomimetic for the treatment of neurological disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU734827B2 (en) * | 1997-05-21 | 2001-06-21 | Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| JP2007526316A (ja) * | 2004-03-01 | 2007-09-13 | ルーメン セラピューティックス リミテッド ライアビリティ カンパニー | 疾患を処置するための組成物および方法 |
| AU2008293496A1 (en) * | 2007-08-27 | 2009-03-05 | Kai Pharmaceuticals, Inc. | Protein kinase C-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation |
| JP5816550B2 (ja) * | 2009-06-22 | 2015-11-18 | 株式会社メディネット | 蛋白質の修飾剤 |
| JP5270799B2 (ja) * | 2009-07-29 | 2013-08-21 | カイ・ファーマシューティカルズ・インコーポレイテッド | 副甲状腺ホルモンを低減する治療剤 |
| US20110053829A1 (en) * | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CA2870711A1 (en) | 2012-04-17 | 2013-10-24 | Brown University | Neuroprotective composition and method of use |
-
2013
- 2013-04-17 CA CA2870711A patent/CA2870711A1/en not_active Abandoned
- 2013-04-17 EP EP13777758.7A patent/EP2872160A4/en not_active Withdrawn
- 2013-04-17 WO PCT/US2013/036938 patent/WO2013158739A1/en not_active Ceased
- 2013-04-17 AU AU2013249337A patent/AU2013249337A1/en not_active Abandoned
- 2013-04-17 JP JP2015507143A patent/JP2015514771A/ja active Pending
- 2013-04-17 US US14/391,293 patent/US20150126457A1/en not_active Abandoned
-
2016
- 2016-12-29 US US15/393,720 patent/US10040822B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013158739A1 (en) | 2013-10-24 |
| US20170107253A1 (en) | 2017-04-20 |
| EP2872160A1 (en) | 2015-05-20 |
| AU2013249337A1 (en) | 2014-10-30 |
| JP2015514771A (ja) | 2015-05-21 |
| EP2872160A4 (en) | 2015-11-25 |
| US10040822B2 (en) | 2018-08-07 |
| US20150126457A1 (en) | 2015-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10040822B2 (en) | Neuroprotective composition and method of use | |
| McManus et al. | Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders | |
| EP3615057B1 (en) | Dosing regimen for treatment of cognitive impairments with blood plasma products | |
| WO2007108541A1 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
| US20180207227A1 (en) | Therapeutic and Neuroprotective Peptides | |
| AU2019306477A1 (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
| JP2021530570A (ja) | てんかん、発作および中枢神経系障害を治療するための経口抗炎症性ペプチド | |
| Dudin et al. | Scorpion sting in children in the Jerusalem area: a review of 54 cases | |
| Sandstrom | Secondary reactions from contrast media and the allergy concept | |
| KR20250004041A (ko) | 삼차 신경통 치료 및 그와 관련된 통증 감소에 사용하기 위한 트리메프라진 | |
| WO2018129231A1 (en) | Method for treating multiple sclerosis | |
| WO2022094565A1 (en) | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders | |
| US11759451B2 (en) | Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury | |
| Kaity et al. | Antioxidants in brain injury with or without antibiotics | |
| Kanthasamy et al. | Antimyoclonic and neuroprotective effects of lamotrigine in an animal model of cardiac arrest | |
| TWI306770B (en) | Pharmaceutical composition for rescuring learning or memory deficits | |
| WO2024249800A1 (en) | Compositions of blood plasma fractions and blood plasma subfractions and their use in treatment of disease | |
| Genis | Neuroprotective Agents for Traumatic Brain Injury: Theoretical Therapy or the Future of Treatment? | |
| CN110234335B (zh) | 治疗女性性功能障碍的药物组合物和方法 | |
| Al-Humaidan et al. | Can propofol cause dystonia and movement disorders? | |
| RU2494707C2 (ru) | Способ лечения открытоугольной глаукомы | |
| US20240316143A1 (en) | Therapeutic agents and/or pharmaceutical compositions for neurocognitive disorders | |
| RU2502503C1 (ru) | Способ лечения спастичности, сопровождающийся улучшением сознания у больных в вегетативном состоянии | |
| Zahedi et al. | The effect of oral clonidine pretreatment on intraocular pressure and hemodynamic stability after succinylcholine injection and intubation in cataract surgery | |
| Perera et al. | in the vit tion. A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180227 |
|
| FZDE | Discontinued |
Effective date: 20200831 |